secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0001493152-22-007956
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports 2021 revenue $5.2M, net loss $20.2M; cash $53.8M; pipeline milestones set
--------------------------------------------------------------------------------

- Revenue $5.2M in 2021 vs $12.6M in 2020; net loss $20.2M vs $19.3M; EPS ($8.63).
- Cash $53.8M at Dec 31, 2021; raised $46.75M in 2021; funded into Q1 2024.
- Hired Dr. Margaret Wasilewski as CMO; completed 1-for-20 reverse stock split; regained Nasdaq compliance.
- Pulmazole Phase 2b in ABPA to start Q1 2023, data mid-2024; PUR3100 Phase 1 in Australia Q3 2022.
- PUR1800 Phase 1b met safety endpoint; preclinical tox supports chronic dosing in COPD, asthma, IPF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222007956/0001493152-22-007956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222007956/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-007956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer